List of Excipients in Branded Drug DIFLUCAN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Roerig	DIFLUCAN	fluconazole	0049-3410	ALUMINUM OXIDE
Roerig	DIFLUCAN	fluconazole	0049-3410	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Roerig	DIFLUCAN	fluconazole	0049-3410	CELLULOSE, MICROCRYSTALLINE
Roerig	DIFLUCAN	fluconazole	0049-3410	CROSCARMELLOSE SODIUM
Roerig	DIFLUCAN	fluconazole	0049-3410	FD&C RED NO. 40
Roerig	DIFLUCAN	fluconazole	0049-3410	MAGNESIUM STEARATE
Roerig	DIFLUCAN	fluconazole	0049-3410	POVIDONE

Diflucan Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 27, 2026

Diflucan, Pfizer’s brand of fluconazole, has limited residual patent protection and faces extensive generic competition. The commercial opportunity is therefore concentrated in formulation differentiation, supply reliability, pediatric and outpatient convenience, preservative-free delivery, and excipient optimization rather than in exclusivity over fluconazole itself. The principal U.S. dosage forms are immediate-release tablets, oral suspension powder, and intravenous injection.[1]

What excipients are used in Diflucan tablets?

Diflucan tablets use conventional direct-compression or wet-granulation excipients with no apparent exclusivity value. The U.S. label identifies lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate as inactive ingredients.[1]

Function	Diflucan tablet excipient	Commercial role
Diluent	Lactose monohydrate	Tablet mass and compressibility
Diluent and binder	Microcrystalline cellulose	Mechanical strength and disintegration support
Binder	Povidone	Granule and tablet cohesion
Superdisintegrant	Croscarmellose sodium	Rapid tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate	Ejection from tablet tooling

Diflucan tablets are available in 50 mg, 100 mg, 150 mg, and 200 mg strengths in the U.S. label.[1] The excipient system is broadly standard for generic development. A manufacturer can generally pursue an ANDA if the product matches the reference listed drug in active ingredient, dosage form, strength, route, labeling requirements, and relevant performance characteristics.[2]

Which tablet excipients create the main development risks?

Lactose is the main compatibility and patient-use consideration. It can matter for patients with severe lactose intolerance, although the amount per tablet is usually materially below dietary exposure. A lactose-free generic may have commercial value in institutional formularies, pediatric prescribing, and patient-specific medication programs.

Magnesium stearate concentration and blending time can affect dissolution. Excessive lubrication can reduce tablet wettability and slow release. Povidone level and grade influence hardness and disintegration. Croscarmellose sodium particle size and incorporation method can change dissolution across manufacturing sites.

For a generic applicant, the highest-value excipient controls are:

• blend uniformity at low-dose strengths;
• tablet hardness and friability;
• dissolution similarity across all strengths;
• moisture control for lactose-containing blends;
• lubricant exposure time;
• packaging protection against humidity.

The 150 mg tablet has particular commercial relevance because it is widely used as a single-dose regimen for vulvovaginal candidiasis. Packaging convenience, low tablet friability, and reliable availability can have greater commercial impact than a novel excipient.

What excipients are used in Diflucan oral suspension?

Diflucan powder for oral suspension uses sucrose, colloidal silicon dioxide, titanium dioxide, xanthan gum, sodium citrate, citric acid, sodium benzoate, and natural orange flavor, according to the U.S. prescribing information.[1]

The product is reconstituted to 10 mg/mL or 40 mg/mL, depending on the marketed presentation.[1] The excipient system supports powder flow, suspension stability, microbial protection, pH control, opacity, and palatability.

Excipient	Primary function	Commercial and regulatory issue
Sucrose	Bulking agent and sweetener	Dental exposure, sugar restrictions, caloric load
Xanthan gum	Suspending and viscosity agent	Pourability, syringe withdrawal, sedimentation
Colloidal silicon dioxide	Powder flow and suspension aid	Dispersion and processing control
Sodium citrate	Buffer	pH control and taste
Citric acid	Acidulant and buffer component	Taste, pH, chemical stability
Sodium benzoate	Preservative	Regulatory limits and preservative efficacy
Titanium dioxide	Opacifier and colorant	Jurisdiction-specific regulatory treatment
Natural orange flavor	Taste masking	Flavor availability and sensory consistency

What formulation opportunities exist for Diflucan oral suspension?

The oral suspension is the strongest excipient-driven opportunity because pediatric and dysphagia patients often experience difficulty with bitter or poorly wetting suspensions. Commercially relevant improvements include:

1. Sugar-reduced or sugar-free suspension.
   Replacing sucrose with a polyol, high-intensity sweetener, or combination system could address dental-care and metabolic concerns. The formulation must preserve viscosity, dose uniformity, preservative performance, and acceptable taste.

2. Improved taste masking.
   Fluconazole has a bitter taste. Ion-pairing, polymeric coating, cyclodextrin complexation, flavor modulation, or multiparticulate approaches could improve pediatric acceptance. These changes may increase regulatory complexity if they alter dissolution or systemic exposure.

3. Ready-to-use liquid.
   A ready-to-use product eliminates reconstitution errors and reduces pharmacy workload. The tradeoff is higher shipping weight, greater microbial-control burden, and potentially shorter shelf life.

4. Low-volume concentration.
   A higher concentration can reduce administration volume for children. The product must maintain dose homogeneity after repeated withdrawals and avoid excessive viscosity that impairs oral syringe accuracy.

5. Preservative-reduced or preservative-free presentation.
   This is commercially attractive for selected pediatric and institutional markets but requires robust container-closure and microbiological controls. A preservative-free multidose suspension is technically more difficult than a single-use or unit-dose product.

6. Excipient simplification.
   Removing titanium dioxide, sodium benzoate, or specific flavors can support regional registration and reduce supply-chain exposure. The replacement must preserve appearance, microbial quality, and sensory performance.

What FDA regulatory pathway applies to a new Diflucan formulation?

A conventional fluconazole tablet with the same dosage form, strength, route, and pharmaceutical equivalence profile would typically be developed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[2]

A materially differentiated liquid, modified concentration, novel excipient system, or new delivery presentation may require a 505(b)(2) application if the sponsor relies partly on FDA findings for an approved fluconazole product while introducing changes that cannot be supported through ANDA procedures.[3]

Product concept	Likely pathway	Main evidence burden
Conventional immediate-release tablet	ANDA	Pharmaceutical equivalence, bioequivalence, CMC
Generic powder for suspension	ANDA	Reconstitution, dose uniformity, dissolution, stability
Sugar-free suspension with same clinical use	ANDA or 505(b)(2), depending on formulation and equivalence	Excipients, taste, stability, bioequivalence
Ready-to-use liquid	Potentially 505(b)(2)	Stability, microbiology, bioavailability, product-specific clinical rationale
New delivery device or substantially different concentration	Often 505(b)(2)	Device performance, dose delivery, clinical bridging
New indication or dosing regimen	505(b)(2) or supplemental application	Clinical and labeling support
New intravenous container or premix	ANDA or 505(b)(2)	Container compatibility, sterility, particulate matter, stability

The FDA Inactive Ingredient Database can support excipient selection, but an excipient’s prior use does not eliminate the need to establish safety and product performance in the proposed formulation.[4]

What patents protect Diflucan and its formulations?

The core fluconazole patent estate is expired in the United States. The historical composition-of-matter patent commonly associated with fluconazole is U.S. Patent No. 4,404,216, assigned to Pfizer and directed to triazole antifungal compounds including fluconazole.[5] The patent does not create a current U.S. barrier to ordinary fluconazole generic development.

IP category	Diflucan position	Commercial significance
Fluconazole composition of matter	Expired	No current U.S. molecule-level exclusivity
Original Diflucan product patents	Expired or commercially exhausted	No meaningful barrier to standard generics
Oral tablet excipients	Conventional and generally non-proprietary	Limited differentiation value
Suspension excipient system	Potentially reproducible, but not an effective molecule barrier	Opportunity for formulation design
Intravenous saline presentation	Mature technology	Low patent barrier, higher manufacturing and quality burden
New taste-masking or delivery technology	Potentially patentable	Can support 505(b)(2) differentiation
Manufacturing process improvements	Potentially patentable	May protect cost, yield, impurity control, or scale-up

The Orange Book is the primary FDA source for listed patents and exclusivity associated with approved products.[6] Diflucan’s commercial position is no longer driven by listed patents covering fluconazole itself. Any current freedom-to-operate analysis should focus on third-party formulation, device, manufacturing, and excipient-technology patents rather than on the expired fluconazole molecule patent.

When did Diflucan lose exclusivity?

Diflucan lost meaningful U.S. molecule-level exclusivity years ago, and fluconazole is now supplied by multiple generic manufacturers. Pfizer’s branded product remains relevant for reference-product status, prescribing familiarity, and channel presence, but the generic market determines price and availability.

Milestone	Approximate position
Original fluconazole patent issued	1983
Diflucan U.S. approval	1990
Core U.S. patent protection	Expired
Current U.S. market	Mature generic market
Current biosimilar exclusivity	Not applicable

Fluconazole is a small-molecule drug, not a biologic. Biosimilar risk therefore does not apply. The relevant competitive threat is generic substitution and, for differentiated products, competition from other oral and intravenous antifungal therapies.

Which companies are challenging Diflucan through Paragraph IV filings?

The mature fluconazole market has included multiple ANDA sponsors and generic suppliers. Paragraph IV litigation is not the principal current market issue because the core U.S. patent estate has expired. New Paragraph IV activity would more likely involve a newly patented formulation, delivery device, or method of use rather than fluconazole itself.

For a new excipient-based product, Paragraph IV risk can arise if the reference product or a competing branded formulation lists a later-expiring formulation patent in the Orange Book. A sponsor seeking early launch would need to evaluate:

• listed formulation patents;
• method-of-use patents;
• patent-use codes;
• non-infringement and invalidity positions;
• 30-month stay exposure;
• settlement restrictions;
• whether the proposed label carves out the patented use.

There is no commercial reason to treat Diflucan’s expired core patent as an obstacle to a conventional fluconazole ANDA.

What is the litigation and settlement position for Diflucan?

Diflucan’s important historical patent disputes were associated with generic entry before expiration of the original patent estate. The current commercial landscape is dominated by generic competition rather than an active originator-versus-generic dispute over the fluconazole molecule.

Settlement analysis is more relevant for a new branded formulation. A sponsor developing a sugar-free, ready-to-use, taste-masked, or device-enabled product should assess whether the product will be listed as a separate reference product and whether its formulation claims could support enforcement against later ANDA or 505(b)(2) entrants.

No biosimilar settlement framework applies to Diflucan.

How strong is the Diflucan patent estate?

The patent estate is weak for molecule-level exclusivity and stronger only as a historical reference point. Commercial strength now depends on brand recognition, manufacturing scale, hospital contracting, regulatory history, and distribution.

Estate component	Strength today	Reason
Active ingredient	Low	Core patent protection expired
Standard tablets	Low	Mature generic manufacturing
Oral suspension	Low to moderate	Formulation know-how may matter, but conventional excipients are reproducible
Injection	Low patent strength, high quality burden	Sterility and compatibility create execution barriers
New excipient technology	Potentially moderate to high	Patentability depends on novelty and non-obvious performance
Manufacturing process	Moderate	Cost and impurity advantages can be defensible if technically distinctive

The most defensible IP strategy would focus on measurable product advantages: reduced sedimentation, improved dose recovery, superior taste scores, longer in-use stability, reduced preservative load, lower administration volume, or improved container compatibility.

What commercial opportunities exist in Diflucan excipient reformulation?

Pediatric oral suspension

The highest-value opportunity is a pediatric suspension with improved palatability, dose accuracy, and simplified administration. A product that reduces reconstitution errors and improves adherence could compete on pharmacy and caregiver convenience rather than price alone.

Key development targets include:

• low sedimentation rate;
• rapid redispersion after standing;
• accurate delivery through oral syringes;
• stable viscosity across temperature ranges;
• acceptable taste after repeated dosing;
• robust preservative efficacy;
• clear instructions for storage and discard timing.

Hospital and outpatient injection

Fluconazole injection is a mature intravenous product. Opportunities include ready-to-use bags, optimized container sizes, reduced overfill, improved labeling, and supply-chain resilience. The primary barriers are sterile manufacturing, particulate control, extractables and leachables, container compatibility, and validated stability.

A premixed product can reduce pharmacy compounding and preparation time. However, it competes with established generic injection suppliers and must offer reliable availability or measurable operational savings.

Geriatric and dysphagia formulations

Older patients and patients receiving enteral nutrition may benefit from an oral liquid with lower administration volume, improved syringe compatibility, and reduced sugar content. The formulation must address tube compatibility, adsorption, clogging, and dose recovery.

International excipient harmonization

Titanium dioxide, preservatives, flavors, and sugar systems face different regulatory and commercial treatment across jurisdictions. A platform formulation with regionally interchangeable excipient modules could lower registration and supply-chain costs. The formulation must still meet local requirements for permitted colors, preservatives, allergens, labeling, and pharmaceutical-grade excipients.

How does Diflucan compare with competing antifungal drugs?

Fluconazole competes with itraconazole, voriconazole, posaconazole, isavuconazole, and echinocandins. Its commercial advantages are established oral and intravenous use, broad generic availability, and relatively simple formulation requirements. Its limitations include resistance in some Candida species, clinically important drug interactions, and narrower activity against certain molds.

Product class	Excipient opportunity	Commercial constraint
Fluconazole tablets	Conventional tablet optimization	Strong generic price pressure
Fluconazole suspension	Taste, sugar reduction, concentration	Pediatric market size and bioequivalence complexity
Fluconazole injection	Ready-to-use packaging and stability	Sterile manufacturing and hospital contracts
Posaconazole suspension/tablet	Solubility and absorption optimization	More complex formulation and clinical positioning
Voriconazole	Pediatric liquid and taste masking	Safety, interactions, and formulation complexity
Echinocandins	Parenteral presentation	No oral option and higher treatment cost

Fluconazole’s low cost limits premium pricing. A differentiated product therefore needs a clear economic benefit, such as fewer preparation steps, lower waste, improved adherence, or reduced administration errors.

What generic launch risks exist for a new Diflucan product?

The main risks are regulatory and commercial rather than molecule-level patent risk.

Risk	Impact	Mitigation
Taste-masking technology changes exposure	ANDA or 505(b)(2) failure	Early comparative bioavailability and dissolution work
Suspension segregation	Dose inaccuracy	Rheology, particle-size, and redispersion controls
Preservative failure	Product recall or approval delay	Preservative efficacy testing and validated packaging
Excipient supply disruption	Batch interruption	Dual sourcing and qualified alternatives
Flavor inconsistency	Pediatric rejection	Sensory controls and supplier qualification
Low-cost generic competition	Margin compression	Contract, convenience, or supply differentiation
Device incompatibility	Dose-delivery failure	Human-factors and container-device studies
Regional excipient restrictions	Registration delay	Jurisdiction-specific formulation variants

What are the revenue and licensing opportunities?

The strongest licensing targets are technologies that solve a recognized formulation problem and can be protected independently of fluconazole’s expired composition patent. Relevant assets include:

• pediatric taste-masking platforms;
• sugar-free suspension systems;
• unit-dose oral liquid packaging;
• ready-to-use sterile premix systems;
• low-volume dosing technologies;
• preservative-free multidose packaging;
• excipient systems that improve redispersion or dose uniformity;
• manufacturing processes that reduce fluconazole impurity formation.

Licensing value is likely to be higher for a platform applicable to several antifungals than for a fluconazole-only product. A fluconazole-only asset faces a mature low-price market and limited reimbursement leverage.

Potential counterparties include generic manufacturers, hospital-product companies, specialty pharmacies, contract development and manufacturing organizations, and companies with pediatric drug-delivery portfolios. A formulation license should define ownership of new patents, regulatory data, manufacturing improvements, supplier changes, and geographic rights.

Key Takeaways

• Diflucan’s fluconazole composition patent protection is expired.
• The U.S. market is genericized, so conventional tablets have limited margin and patent value.
• The oral suspension offers the clearest excipient-led opportunity.
• Sugar reduction, taste masking, lower administration volume, and improved syringe dosing are commercially relevant.
• Intravenous opportunity centers on ready-to-use packaging, sterile supply reliability, and hospital workflow savings.
• Conventional reformulations may fit the ANDA pathway; materially new products may require 505(b)(2) development.
• Biosimilar risk does not apply because fluconazole is a small molecule.
• New value is most defensible through formulation, device, packaging, and manufacturing patents.
• A platform technology applicable to several antifungal products is more licensable than a fluconazole-only formulation.
• Generic price pressure requires measurable adherence, convenience, quality, or supply advantages.

FAQs

Can a lactose-free fluconazole tablet be marketed as a generic Diflucan?

Potentially. The sponsor would need to establish pharmaceutical equivalence, bioequivalence, acceptable inactive-ingredient use, and product performance under the applicable FDA pathway.

Is fluconazole oral suspension a stronger commercial opportunity than fluconazole tablets?

Yes. The suspension has more room for differentiation through taste, sugar content, concentration, reconstitution, dose accuracy, and pediatric usability.

Can a new fluconazole flavor create patent protection?

Flavor alone is usually weak as a patent strategy. A patent position is stronger when the flavor is part of a novel formulation that produces measurable taste-masking, stability, dose-delivery, or adherence benefits.

Does a ready-to-use fluconazole injection require a new clinical trial?

Not necessarily. The required evidence depends on the formulation, container, concentration, route, and regulatory pathway. CMC, sterility, stability, compatibility, and bridging data may be sufficient in some cases.

Is Diflucan still protected by Pfizer exclusivity?

Diflucan retains brand identity and reference-product status, but the core U.S. fluconazole exclusivity has ended. Current competition is primarily from generic manufacturers.

References

1. Pfizer Inc. (2023). Diflucan (fluconazole) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA.

3. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

5. Pfizer Inc. (1983). U.S. Patent No. 4,404,216: Antifungal agents. U.S. Patent and Trademark Office.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.